JP2009528544A - 質量分析法を用いて異性体を識別するための方法 - Google Patents
質量分析法を用いて異性体を識別するための方法 Download PDFInfo
- Publication number
- JP2009528544A JP2009528544A JP2008557381A JP2008557381A JP2009528544A JP 2009528544 A JP2009528544 A JP 2009528544A JP 2008557381 A JP2008557381 A JP 2008557381A JP 2008557381 A JP2008557381 A JP 2008557381A JP 2009528544 A JP2009528544 A JP 2009528544A
- Authority
- JP
- Japan
- Prior art keywords
- adma
- sdma
- subject
- sample
- ions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 220
- 238000004949 mass spectrometry Methods 0.000 title claims description 21
- 150000002500 ions Chemical class 0.000 claims abstract description 225
- HVPFXCBJHIIJGS-LURJTMIESA-N N(omega),N'(omega)-dimethyl-L-arginine Chemical compound CN\C(=N/C)NCCC[C@H](N)C(O)=O HVPFXCBJHIIJGS-LURJTMIESA-N 0.000 claims abstract description 192
- YDGMGEXADBMOMJ-LURJTMIESA-N N(g)-dimethylarginine Chemical compound CN(C)C(\N)=N\CCC[C@H](N)C(O)=O YDGMGEXADBMOMJ-LURJTMIESA-N 0.000 claims abstract description 181
- YDGMGEXADBMOMJ-UHFFFAOYSA-N asymmetrical dimethylarginine Natural products CN(C)C(N)=NCCCC(N)C(O)=O YDGMGEXADBMOMJ-UHFFFAOYSA-N 0.000 claims abstract description 157
- NWGZOALPWZDXNG-LURJTMIESA-N (2s)-5-(diaminomethylideneamino)-2-(dimethylamino)pentanoic acid Chemical class CN(C)[C@H](C(O)=O)CCCNC(N)=N NWGZOALPWZDXNG-LURJTMIESA-N 0.000 claims abstract description 43
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 36
- 239000000203 mixture Substances 0.000 claims abstract description 27
- 239000000523 sample Substances 0.000 claims description 127
- 239000012472 biological sample Substances 0.000 claims description 61
- 206010020772 Hypertension Diseases 0.000 claims description 48
- 230000002503 metabolic effect Effects 0.000 claims description 48
- 208000019553 vascular disease Diseases 0.000 claims description 47
- 150000001875 compounds Chemical class 0.000 claims description 46
- 210000004027 cell Anatomy 0.000 claims description 44
- 206010059245 Angiopathy Diseases 0.000 claims description 41
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 36
- 239000004475 Arginine Substances 0.000 claims description 30
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 30
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 25
- 210000004369 blood Anatomy 0.000 claims description 24
- 239000008280 blood Substances 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 24
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 20
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 19
- 235000001014 amino acid Nutrition 0.000 claims description 19
- 150000001413 amino acids Chemical class 0.000 claims description 19
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 18
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 18
- 229960002173 citrulline Drugs 0.000 claims description 18
- 235000013477 citrulline Nutrition 0.000 claims description 18
- 241000124008 Mammalia Species 0.000 claims description 17
- 201000011461 pre-eclampsia Diseases 0.000 claims description 17
- 210000002966 serum Anatomy 0.000 claims description 16
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 15
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 15
- 238000004885 tandem mass spectrometry Methods 0.000 claims description 14
- 229940124597 therapeutic agent Drugs 0.000 claims description 14
- 206010036790 Productive cough Diseases 0.000 claims description 13
- 210000004381 amniotic fluid Anatomy 0.000 claims description 13
- 210000001185 bone marrow Anatomy 0.000 claims description 13
- 230000002490 cerebral effect Effects 0.000 claims description 13
- 210000003097 mucus Anatomy 0.000 claims description 13
- 210000002381 plasma Anatomy 0.000 claims description 13
- 210000003296 saliva Anatomy 0.000 claims description 13
- 210000003802 sputum Anatomy 0.000 claims description 13
- 208000024794 sputum Diseases 0.000 claims description 13
- 210000001138 tear Anatomy 0.000 claims description 13
- 210000002700 urine Anatomy 0.000 claims description 13
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 12
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 12
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 12
- 210000002751 lymph Anatomy 0.000 claims description 12
- 229960003104 ornithine Drugs 0.000 claims description 12
- 239000013074 reference sample Substances 0.000 claims description 12
- 210000004243 sweat Anatomy 0.000 claims description 12
- 150000007524 organic acids Chemical class 0.000 claims description 11
- 229960003624 creatine Drugs 0.000 claims description 10
- 239000006046 creatine Substances 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 10
- 230000008085 renal dysfunction Effects 0.000 claims description 9
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 8
- 239000002220 antihypertensive agent Substances 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 201000001320 Atherosclerosis Diseases 0.000 claims description 7
- 229940030600 antihypertensive agent Drugs 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 235000006408 oxalic acid Nutrition 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 5
- 229940124549 vasodilator Drugs 0.000 claims description 5
- 239000003071 vasodilator agent Substances 0.000 claims description 5
- 239000005541 ACE inhibitor Substances 0.000 claims description 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 4
- 239000002160 alpha blocker Substances 0.000 claims description 4
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 claims description 4
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 4
- 239000003529 anticholesteremic agent Substances 0.000 claims description 4
- 229940127226 anticholesterol agent Drugs 0.000 claims description 4
- 239000002876 beta blocker Substances 0.000 claims description 4
- 229940097320 beta blocking agent Drugs 0.000 claims description 4
- 239000002934 diuretic Substances 0.000 claims description 4
- 229940030606 diuretics Drugs 0.000 claims description 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 3
- 229910052805 deuterium Inorganic materials 0.000 claims description 3
- 210000002889 endothelial cell Anatomy 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 229940127088 antihypertensive drug Drugs 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 238000001542 size-exclusion chromatography Methods 0.000 claims description 2
- 230000007704 transition Effects 0.000 description 18
- 238000002552 multiple reaction monitoring Methods 0.000 description 17
- 230000006870 function Effects 0.000 description 16
- 208000030159 metabolic disease Diseases 0.000 description 16
- 239000012634 fragment Substances 0.000 description 12
- 239000012491 analyte Substances 0.000 description 11
- 238000001514 detection method Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000001819 mass spectrum Methods 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- -1 orthonitine Chemical compound 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 6
- 102000008052 Nitric Oxide Synthase Type III Human genes 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000002526 effect on cardiovascular system Effects 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- NTNWOCRCBQPEKQ-UHFFFAOYSA-N NG-mono-methyl-L-arginine Natural products CN=C(N)NCCCC(N)C(O)=O NTNWOCRCBQPEKQ-UHFFFAOYSA-N 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000008753 endothelial function Effects 0.000 description 4
- 230000003862 health status Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000001212 derivatisation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010070538 Gestational hypertension Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229960003121 arginine Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000035606 childbirth Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000001360 collision-induced dissociation Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 108010087765 Antipain Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 201000005624 HELLP Syndrome Diseases 0.000 description 1
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 101710085388 N(G),N(G)-dimethylarginine dimethylaminohydrolase Proteins 0.000 description 1
- 102100035854 N(G),N(G)-dimethylarginine dimethylaminohydrolase 1 Human genes 0.000 description 1
- NTWVQPHTOUKMDI-YFKPBYRVSA-N N-Methyl-arginine Chemical compound CN[C@H](C(O)=O)CCCN=C(N)N NTWVQPHTOUKMDI-YFKPBYRVSA-N 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 208000002787 Pregnancy Complications Diseases 0.000 description 1
- 208000005347 Pregnancy-Induced Hypertension Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical group O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- VVGPECAOVDZTLZ-UHFFFAOYSA-N [N]NC(N)=N Chemical group [N]NC(N)=N VVGPECAOVDZTLZ-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MBXXQYJBFRRFCK-UHFFFAOYSA-N benzyl fluoride Chemical compound FCC1=CC=CC=C1 MBXXQYJBFRRFCK-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000002296 eclampsia Diseases 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000004578 fetal growth Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 231100000640 hair analysis Toxicity 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003225 hyperhomocysteinemia Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 238000004750 isotope dilution mass spectroscopy Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000000608 laser ablation Methods 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 201000005857 malignant hypertension Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- WEFCHZVJIDHTIY-UHFFFAOYSA-N n-(1h-indol-3-ylmethyl)-n-methylnitrous amide Chemical compound C1=CC=C2C(CN(C)N=O)=CNC2=C1 WEFCHZVJIDHTIY-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 208000036335 preeclampsia/eclampsia 1 Diseases 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000004844 protein turnover Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 206010038464 renal hypertension Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77848306P | 2006-03-02 | 2006-03-02 | |
| PCT/US2007/005279 WO2007103124A2 (en) | 2006-03-02 | 2007-03-02 | Methods for distinguishing isomers using mass spectrometry |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009528544A true JP2009528544A (ja) | 2009-08-06 |
| JP2009528544A5 JP2009528544A5 (https=) | 2010-04-15 |
Family
ID=38475391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008557381A Pending JP2009528544A (ja) | 2006-03-02 | 2007-03-02 | 質量分析法を用いて異性体を識別するための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20080073500A1 (https=) |
| EP (1) | EP1996923B1 (https=) |
| JP (1) | JP2009528544A (https=) |
| CN (1) | CN101438148B (https=) |
| AU (1) | AU2007224240B2 (https=) |
| BR (1) | BRPI0708485A2 (https=) |
| CA (1) | CA2644499A1 (https=) |
| DK (1) | DK1996923T3 (https=) |
| ES (1) | ES2392629T3 (https=) |
| WO (1) | WO2007103124A2 (https=) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012520463A (ja) * | 2009-03-10 | 2012-09-06 | デューク ユニバーシティ | 冠動脈疾患および心血管イベントのリスクの予測 |
| JP2012528340A (ja) * | 2009-05-28 | 2012-11-12 | ザ クリーブランド クリニック ファウンデーション | 疾患の診断および予測のためのトリメチルアミン含有化合物 |
| JP2012529015A (ja) * | 2009-06-02 | 2012-11-15 | バイオクラテス ライフ サイエンシーズ アーゲー | 腎臓疾患評価用新規バイオマーカー |
| JP2013515255A (ja) * | 2009-12-21 | 2013-05-02 | ユニバーシティ カレッジ コーク ナショナル ユニバーシティ オブ アイルランド コーク | 妊娠高血圧腎症の危険性の検出 |
| JP2013522649A (ja) * | 2010-03-22 | 2013-06-13 | ステミナ バイオマーカー ディスカバリー， インコーポレイテッド | ヒト幹細胞様細胞及びメタボロミクスを使用した医薬のヒト発生毒性の予測 |
| JP2014520265A (ja) * | 2011-06-16 | 2014-08-21 | ベイラー リサーチ インスティテュート | 血漿分離デバイス（ｐｓｄ）から得られる血漿中の総ホモシステイン及びメチルマロン酸のｌｃ−ｍｓ／ｍｓによる分析 |
| WO2020090887A1 (ja) * | 2018-11-02 | 2020-05-07 | 国立大学法人神戸大学 | 分析方法、吸着防止剤および分析用キット |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005056408B4 (de) * | 2005-05-28 | 2007-05-31 | Esa Patentverwertungsagentur Sachsen-Anhalt Gmbh | Verfahren zur Bestimmung der Konzentration von asymmetrischem Dimethylarginin (ADMA) |
| JP2010540911A (ja) * | 2007-10-01 | 2010-12-24 | ディーエイチ テクノロジーズ デベロップメント プライベート リミテッド | アルコール消費の複合化した代謝産物の分析 |
| AU2015258285B2 (en) * | 2009-03-10 | 2017-09-07 | Duke University | Predicting coronary artery disease and risk of cardiovascular events |
| WO2010108180A2 (en) * | 2009-03-20 | 2010-09-23 | The Cleveland Clinic Foundation | Citrulline, a risk indicator for cardiovascular disease |
| EP2436025A1 (en) * | 2009-05-27 | 2012-04-04 | DH Technologies Development Pte. Ltd. | Linear ion trap for msms |
| EP2443456A4 (en) * | 2009-06-15 | 2013-02-20 | Cleveland Clinic Foundation | METABOLITES OF ARGININE METHYLATES AS PREDICTORS OF CARDIOVASCULAR DISEASE RISK |
| CN107064330B (zh) * | 2010-12-28 | 2022-02-25 | 探索诊断投资公司 | 通过质谱法定量胰岛素 |
| CN102154444B (zh) * | 2010-12-30 | 2013-09-25 | 北京九强生物技术股份有限公司 | 测定不对称二甲基精氨酸浓度的方法及诊断试剂盒 |
| WO2013140785A1 (ja) * | 2012-03-18 | 2013-09-26 | 国立大学法人九州大学 | 疾患サンプル分析装置、分析システム及び分析方法 |
| CN103207173B (zh) * | 2013-03-13 | 2015-06-17 | 北大工学院绍兴技术研究院 | 一种酶学检测方法 |
| WO2015044958A1 (en) | 2013-09-25 | 2015-04-02 | Council Of Scientific & Industrial Research | Quantitation of structural isomers using maldi ms/ms |
| JP6647224B2 (ja) | 2014-06-13 | 2020-02-14 | ディーエイチ テクノロジーズ デベロップメント プライベート リミテッド | 質量分析を用いる脂質の分析のための方法 |
| EP3259593B1 (en) * | 2015-02-20 | 2022-10-05 | IDEXX Laboratories, Inc. | Homogenous immunoassay with compensation for background signal |
| WO2016149220A1 (en) | 2015-03-13 | 2016-09-22 | Duke University | Compositions and methods for metabolic profiling in subjects with heart failure with preserved ejection fraction |
| CN104849298B (zh) * | 2015-05-26 | 2017-10-31 | 衢州普林千叶电子科技有限公司 | 一种用于核磁分析的样品检测分析仪和方法 |
| CN105628623B (zh) * | 2015-12-25 | 2018-08-24 | 北京市农林科学院 | 一种鉴别光学异构化合物旋光性的方法 |
| CN107764891B (zh) * | 2017-10-16 | 2020-03-13 | 杭州先导医药科技有限责任公司 | 一种恩替卡韦手性异构体的区分测定方法 |
| US10854438B2 (en) * | 2018-03-19 | 2020-12-01 | Agilent Technologies, Inc. | Inductively coupled plasma mass spectrometry (ICP-MS) with improved signal-to-noise and signal-to-background ratios |
| US20220276263A1 (en) * | 2021-02-19 | 2022-09-01 | Idexx Laboratories, Inc. | Mass spectrometric analysis of biomarkers |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03165446A (ja) * | 1989-11-24 | 1991-07-17 | Shimadzu Corp | 質量分析方法 |
| JP2000111526A (ja) * | 1998-09-30 | 2000-04-21 | Hitachi Ltd | 質量分析計 |
| WO2004078035A2 (en) * | 2003-02-28 | 2004-09-16 | Bayer Pharmaceuticals Corporation | Expression profiles for breast cancer and methods of use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0308967D0 (en) * | 2003-04-17 | 2003-05-28 | Univ London | Screen for pre-eclampsia |
| DE102005056408B4 (de) * | 2005-05-28 | 2007-05-31 | Esa Patentverwertungsagentur Sachsen-Anhalt Gmbh | Verfahren zur Bestimmung der Konzentration von asymmetrischem Dimethylarginin (ADMA) |
-
2007
- 2007-03-02 CA CA002644499A patent/CA2644499A1/en not_active Abandoned
- 2007-03-02 CN CN200780016028.2A patent/CN101438148B/zh active Active
- 2007-03-02 JP JP2008557381A patent/JP2009528544A/ja active Pending
- 2007-03-02 AU AU2007224240A patent/AU2007224240B2/en active Active
- 2007-03-02 EP EP07752007A patent/EP1996923B1/en active Active
- 2007-03-02 BR BRPI0708485-4A patent/BRPI0708485A2/pt not_active IP Right Cessation
- 2007-03-02 US US11/681,744 patent/US20080073500A1/en not_active Abandoned
- 2007-03-02 DK DK07752007.0T patent/DK1996923T3/da active
- 2007-03-02 ES ES07752007T patent/ES2392629T3/es active Active
- 2007-03-02 WO PCT/US2007/005279 patent/WO2007103124A2/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03165446A (ja) * | 1989-11-24 | 1991-07-17 | Shimadzu Corp | 質量分析方法 |
| JP2000111526A (ja) * | 1998-09-30 | 2000-04-21 | Hitachi Ltd | 質量分析計 |
| WO2004078035A2 (en) * | 2003-02-28 | 2004-09-16 | Bayer Pharmaceuticals Corporation | Expression profiles for breast cancer and methods of use |
Non-Patent Citations (4)
| Title |
|---|
| JPN6012019513; ＭＡＲＴＥＮＳ-ＬＯＢＥＮＨＯＦＦＥＲ Ｊ． ｅｔ ａｌ: 'Ｆａｓｔ ａｎｄ Ｅｆｆｉｃｉｅｎｔ Ｄｅｔｅｒｍｉｎａｔｉｏｎ ｏｆ Ａｒｇｉｎｉｎｅ， Ｓｙｍｍｅｔｒｉｃ Ｄｉｍｅｔｈｙｌａｒｇｉｎｉｎｅ， ａｎｄ Ａｓｙｍｍｅｔｒｉｃ Ｄｉｍｅｔｈｙｌａｒｇ' Ｃｌｉｎｉｃａｌ Ｃｈｅｍｉｓｔｒｙ ５２， Ｎｏ．３, 2006, Ｐａｇｅｓ ４８８-４９３ * |
| JPN6012019516; ＴＥＲＡＤＡ Ｎ ｅｔ ａｌ: 'Ｍｅａｓｕｒｅｍｅｎｔ ｏｆ ｃａｒｎｉｔｉｎｅ ｐｒｅｃｕｒｓｏｒｓ， epsilon-ｔｒｉｍｅｔｈｙｌｌｙｓｉｎｅ ａｎｄ gamma-ｂｕｔｙｒｏｂｅｔａｉｎｅ ｉｎ ｈｕｍａｎ ｓｅｒｕｍ ｂｙ ｔａｎｄｅ' Ｊｏｕｒｎａｌ ｏｆ Ｃｈｒｏｍａｔｏｇｒａｐｈｙ Ｂ Ｖｏｌ．７３１， Ｎｏ．１, 1999, Ｐａｇｅｓ ８９-９５ * |
| JPN6012019518; ＴＳＩＫＡＳ Ｄ ｅｔ ａｌ: 'Ｑｕａｎｔｉｔａｔｉｖｅ ｄｅｔｅｒｍｉｎａｔｉｏｎ ｏｆ ｃｉｒｃｕｌａｔｉｎｇ ａｎｄ ｕｒｉｎａｒｙ ａｓｙｍｍｅｔｒｉｃ ｄｉｍｅｔｈｙｌａｒｇｉｎｉｎｅ （ＡＤＭＡ） ｉｎ ｈｕｍａｎｓ ｂ' Ｊｏｕｒｎａｌ ｏｆ Ｃｈｒｏｍａｔｏｇｒａｐｈｙ Ｂ Ｖｏｌ．７９８， Ｎｏ．１, 2003, Ｐａｇｅｓ ８７-９９ * |
| JPN6012019520; ＯＫＵＢＯ Ｋｅｎ ｅｔ ａｌ: 'Ｒｏｌｅ ｏｆ Ａｓｙｍｍｅｔｒｉｃａｌ Ｄｉｍｅｔｈｙｌａｒｇｉｎｉｎｅ ｉｎ Ｒｅｎａｌ Ｍｉｃｒｏｖａｓｃｕｌａｒ Ｅｎｄｏｔｈｅｌｉａｌ Ｄｙｓｆｕｎｃｔｉｏｎ ｉｎ Ｃｈｒｏｎｉｃ Ｒｅｎａ' Ｈｙｐｅｒｔｅｎｓ Ｒｅｓ Ｖｏｌ．２８， Ｎｏ．２, 2005, Ｐａｇｅｓ １８１-１８９ * |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016075705A (ja) * | 2009-03-10 | 2016-05-12 | デューク ユニバーシティ | 冠動脈疾患および心血管イベントのリスクの予測 |
| JP2012520463A (ja) * | 2009-03-10 | 2012-09-06 | デューク ユニバーシティ | 冠動脈疾患および心血管イベントのリスクの予測 |
| JP2012528340A (ja) * | 2009-05-28 | 2012-11-12 | ザ クリーブランド クリニック ファウンデーション | 疾患の診断および予測のためのトリメチルアミン含有化合物 |
| JP2012529015A (ja) * | 2009-06-02 | 2012-11-15 | バイオクラテス ライフ サイエンシーズ アーゲー | 腎臓疾患評価用新規バイオマーカー |
| JP2013515255A (ja) * | 2009-12-21 | 2013-05-02 | ユニバーシティ カレッジ コーク ナショナル ユニバーシティ オブ アイルランド コーク | 妊娠高血圧腎症の危険性の検出 |
| JP2013522649A (ja) * | 2010-03-22 | 2013-06-13 | ステミナ バイオマーカー ディスカバリー， インコーポレイテッド | ヒト幹細胞様細胞及びメタボロミクスを使用した医薬のヒト発生毒性の予測 |
| JP2014520265A (ja) * | 2011-06-16 | 2014-08-21 | ベイラー リサーチ インスティテュート | 血漿分離デバイス（ｐｓｄ）から得られる血漿中の総ホモシステイン及びメチルマロン酸のｌｃ−ｍｓ／ｍｓによる分析 |
| WO2020090887A1 (ja) * | 2018-11-02 | 2020-05-07 | 国立大学法人神戸大学 | 分析方法、吸着防止剤および分析用キット |
| CN112969915A (zh) * | 2018-11-02 | 2021-06-15 | 国立大学法人神户大学 | 分析方法、吸附抑制剂和分析用试剂盒 |
| JPWO2020090887A1 (ja) * | 2018-11-02 | 2021-09-30 | 国立大学法人神戸大学 | 分析方法、吸着防止剤および分析用キット |
| JP7057956B2 (ja) | 2018-11-02 | 2022-04-21 | 国立大学法人神戸大学 | 分析方法、吸着防止剤および分析用キット |
| US11694886B2 (en) | 2018-11-02 | 2023-07-04 | National University Corporation Kobe University | Analysis method, adsorption prevention agent, and analysis kit |
| US12354860B2 (en) | 2018-11-02 | 2025-07-08 | National University Corporation Kobe University | Analysis method, adsorption prevention agent, and analysis kit |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101438148B (zh) | 2014-01-22 |
| CA2644499A1 (en) | 2007-09-13 |
| WO2007103124A3 (en) | 2008-10-09 |
| AU2007224240B2 (en) | 2013-07-25 |
| ES2392629T3 (es) | 2012-12-12 |
| AU2007224240A1 (en) | 2007-09-13 |
| WO2007103124A2 (en) | 2007-09-13 |
| CN101438148A (zh) | 2009-05-20 |
| EP1996923A2 (en) | 2008-12-03 |
| US20080073500A1 (en) | 2008-03-27 |
| EP1996923A4 (en) | 2010-04-07 |
| DK1996923T3 (da) | 2012-10-01 |
| BRPI0708485A2 (pt) | 2011-05-31 |
| EP1996923B1 (en) | 2012-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101438148B (zh) | 利用质谱判别异构体的方法 | |
| Yin et al. | Effects of pre-analytical processes on blood samples used in metabolomics studies | |
| Kushnir et al. | Liquid chromatography–tandem mass spectrometry applications in endocrinology | |
| CA2686202C (en) | Detecting succinylacetone | |
| Nikolic et al. | Metabolomics in hypertension | |
| US8257977B2 (en) | Measuring levels of a metabolite | |
| CN114252547B (zh) | 二甲基甘氨酸作为胎儿先天性心脏病血清标志物的应用 | |
| CN115166125A (zh) | 一种采用超高效液相色谱-串联质谱快速测定人血浆中艾曲泊帕浓度的方法 | |
| CN118090930A (zh) | 基于血液代谢物的阿尔茨海默症标志物及其应用 | |
| AU2014240270B2 (en) | Detecting succinylacetone | |
| CN118091146A (zh) | 基于血液代谢物的神经退行性疾病标志物及其应用 | |
| WO2024108604A1 (zh) | 基于血液代谢物的神经退行性疾病标志物及其应用 | |
| Abbiss | Gas chromatography-mass spectrometry-based untargeted metabolomic analysis of organ tissue, plasma and urine samples from a Rat Model of polycystic kidney disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100226 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100226 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110217 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120417 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120607 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120814 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130115 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130515 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130522 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20130705 |